Combination Of Isoniazid, HAART More Effective At Preventing TB In HIV-Positive Patients Than Monotherapy, Study Says

Main Category: Tuberculosis
Also Included In: HIV / AIDS
Article Date: 18 Aug 2006 - 8:00 PDT

Current ratings for:
'Combination Of Isoniazid, HAART More Effective At Preventing TB In HIV-Positive Patients Than Monotherapy, Study Says'

Patient / Public:1 star

1 (1 votes)

Healthcare Prof:1 star

1 (1 votes)


A combination of the antibiotic isoniazid and highly active antiretroviral therapy is more effective at preventing active tuberculosis among HIV-positive people than the two treatments on their own, according to a study presented Monday at the XVI International AIDS Conference, Health-e News reports. Richard Chaisson, a professor of infectious diseases at Johns Hopkins University, and colleagues examined the medical records of more than 11,000 HIV-positive adults in Rio de Janeiro, Brazil. The researchers found that the risk of developing TB was reduced by 67% among HIV-positive people who took both isoniazid and HAART, while isoniazid on its own reduced the risk of the disease by 32%, and HAART alone reduced the risk of TB by 51%. The researchers also found that the combination is more beneficial among HIV-positive people with lower CD4+T cell counts. The combination reduced the risk of TB by 66% among HIV-positive people with T cell counts below 350, compared with a 56% risk reduction among HIV-positive people with higher T cell counts, according to the study. Chaisson said although the World Health Organization recommends isoniazid to prevent TB among HIV-positive people and the drug costs less than $1 for a full course of treatment, few physicians prescribe it. The researchers say they plan to continue monitoring the effectiveness of the drugs -- both as a combination therapy and as monotherapies -- at preventing the risk of TB among HIV-positive people in Rio de Janeiro. The research is part of three studies by the Bill & Melinda Gates Foundation-funded Consortium To Respond Effectively to the AIDS/TB Epidemic, which aims to develop new ways to detect and treat TB among HIV-positive people (Thom, Health-e News, 8/13).

Kaisernetwork.org is serving as the official webcaster of the conference. View the guide to coverage and all webcasts, interviews and a daily video round up of conference highlights at http://www.kaisernetwork.org/aids2006.

"Reprinted with permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation . © 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.

Article adapted by Medical News Today from original press release.
Visit our tuberculosis section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
Barbara Martin. "Combination Of Isoniazid, HAART More Effective At Preventing TB In HIV-Positive Patients Than Monotherapy, Study Says." Medical News Today. MediLexicon, Intl., 18 Aug. 2006. Web.
26 May. 2012. <http://www.medicalnewstoday.com/releases/49848.php>

APA
Barbara Martin. (2006, August 18). "Combination Of Isoniazid, HAART More Effective At Preventing TB In HIV-Positive Patients Than Monotherapy, Study Says." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/49848.php.

Please note: If no author information is provided, the source is cited instead.



Add Your Opinion On This Article

'Combination Of Isoniazid, HAART More Effective At Preventing TB In HIV-Positive Patients Than Monotherapy, Study Says'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Your Name:*
E-mail Address:*
Your Opinion Title:*
Opinion:*
This is to help prevent SPAM submissions. Please enter the words exactly as they appear, including capital letters and punctuation.*

* Fields marked with a * need to be filled in before you hit the submit button.

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.


Tuberculosis

What Is Tuberculosis?

Tuberculosis (TB) is an infectious disease that is caused by a bacterium called Mycobacterium tuberculosis. TB primarily affects the lungs, but it can also affect organs in the central nervous system, lymphatic system, and circulatory system among others. Read more...

Most Popular Articles



Follow Our Tuberculosis News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Tuberculosis Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »